The global animal biotechnology market was USD 28.17 billion in 2024, rose to USD 30.97 billion in 2025, and is forecast to reach USD 72.6 billion by 2034 — expanding at a CAGR of 9.93% (2025–2034) as vaccines, genetic engineering and recombinant DNA technologies, plus rising demand for animal proteins and stronger animal-health R&D, drive the growth.
Download this Free Sample Now and Get the Complete Report and Insights of this Market Easily @ https://www.towardshealthcare.com/download-sample/5849
Headline figures
●2024: USD 28.17 billion (reported/estimated).
●2025: USD 30.97 billion (reported/estimated).
●2034 (projection): USD 72.6 billion.
Growth trajectory & math check
●Reported CAGR for 2025–2034 = 9.93%.
2024 → 2034 absolute increase
●Increase from 2024 (USD 28.17B) to 2034 (USD 72.6B) ≈ USD 44.43 billion incremental market value over the decade.
Component contributions to size
●Vaccines were the dominant revenue contributor in 2024 (largest single product-type share).
●Genetic engineering and recombinant DNA technologies are major growth engines — genetic engineering led in 2024 and recombinant DNA is expected to grow fastest during the forecast window.
●Animal types: Livestock dominated overall value in 2024; aquaculture is the fastest growth animal type.
Regional contribution / concentration
●North America dominated in 2024 (largest regional share).
●Asia Pacific projected to show the fastest CAGR through the forecast period.
End-user & buyer mix impact on size
●Veterinary clinics were the dominant end-user segment in 2024 (stable, recurring demand).
●Biopharmaceutical companies are the fastest-growing end-user group (scaling R&D, biopharming and therapeutic pipelines).
Why size is expanding (summary)
●Rising global demand for animal protein, increasing regulatory & industry investments in animal health R&D, vaccine adoption, growth of precision breeding/gene-editing, and expanded diagnostics & molecular tools.
Capital & funding acceleration (2024–2025)
●Animab’s EUR 10M Series B (July 2025) — signals investor interest in oral antibody therapeutics for production animals.
●Colossal Biosciences $200M Series C (Jan 2025) — signals large-scale interest (and controversy) in advanced genetic engineering/de-extinction tech.
Vaccine innovation & rollouts
●Vaccines dominate revenue (2024). National/regional launches — e.g., Biovet (Bharat Biotech group) launched a novel vaccine to prevent lumpy skin disease (LSD) in May 2025 — demonstrates continued investment in veterinary biologics.
Diagnostics upgrading
●Focus on molecular and immunodiagnostics: new ELISA kits (Ringbio July 2024) and NIAB’s antibiotics detection diagnostics (Sept 2024) show active diagnostics innovation and food-safety focus.
Consolidation & industrial expansions
●Example: Elanco invested >USD 130 million (Aug 2024) to expand U.S. biologics production — reflects capacity build-out for veterinary biologics.
AI & data driving biotech pipelines
●AI/ML increasingly woven into genetic optimization, disease prediction, imaging and diagnostics (see detailed AI section later).
Regulatory & surveillance emphasis
●UK’s £10M (May 2025) genomics funding (GAP-DC) to strengthen pathogen surveillance underscores the role of genomics in animal/plant biosecurity.
Shift toward sustainable / welfare-oriented biotech
●Consumer pressure on environment and ethics is driving investment into animal-friendly methods, immuno-castration, and welfare-oriented biotech solutions.
Precision breeding & CRISPR adoption
●Gene editing is moving from R&D toward practical productivity and disease-resistance use cases — identified as a top growth opportunity.
Aquaculture & geographic shifts
●Rapid growth in aquaculture biotech (fastest growing animal type) — tied to China’s large aquaculture scale (noted per-capita and tonnage numbers).
Commercialization of transgenic and biopharming
●Expansion of transgenic animal research and biopharming (drug production in animals) driven by pharma interest and biopharmaceutical company involvement.
Genomic selection & predictive breeding
●What: ML models analyze genomic markers + phenotypic data to predict desirable breeding outcomes.
●Benefit: Faster selection for disease resistance, higher feed conversion or improved milk/meat traits; reduces generation time.
●Considerations: Needs high-quality genomic + phenotype datasets, privacy/ownership rules for genetic data.
Gene-editing target discovery
●What: AI prioritizes candidate genes/variants for CRISPR or other edits by integrating multi-omics data.
●Benefit: Speeds discovery of targets that confer disease resistance or productivity traits.
●Considerations: False positives; regulatory scrutiny for edited animals.
Disease surveillance & early outbreak detection
●What: ML flags anomalies in veterinary clinic reports, sentinel farms, environmental sequencing (genomics), and supply-chain signals.
●Benefit: Faster containment, reduced economic losses.
●Considerations: Requires real-time data feeds, cross-jurisdiction data sharing.
Diagnostic interpretation (image & sequence analysis)
●What: AI analyzes microscopic images, pathology slides, or NGS reads to produce rapid, standardized diagnostics.
●Benefit: Faster, more consistent lab outputs (complements ELISA/PCR tests).
●Considerations: Validation datasets and regulatory acceptance.
Vaccine design and optimization
●What: ML helps predict antigenic epitopes, optimize formulations and adjuvant selection.
●Benefit: Shorter R&D cycles for vaccines tailored to circulating strains.
●Considerations: Wet-lab validation needed; dataset biases.
Precision dosing & treatment recommendation engines
●What: AI uses animal weight, physiology, disease risk and pharmacokinetics to suggest personalized dosing.
●Benefit: More effective therapy, reduced resistance risk, improved safety.
●Considerations: Liability and regulatory approval for automated dosing guidance.
Phenotyping automation on farms
●What: Computer vision + sensors measure gait, feeding, behavior, and feed conversion in real time.
●Benefit: Early welfare/disease detection and optimization of management strategies.
●Considerations: Sensor costs, connectivity in remote farms.
Supply-chain optimisation & traceability
●What: AI optimizes logistics for biologics, cold-chain vaccines and diagnostics; integrates traceability for food safety.
●Benefit: Reduced spoilage, faster delivery of perishable biotech products.
●Considerations: Integration with existing logistic systems and regulatory traceability requirements.
R&D automation & lab informatics
●What: ML orchestrates experiment design, automates data capture/analysis and helps prioritize experiments in transgenic research and biopharming.
●Benefit: Reduced bench time, higher R&D throughput (addresses the “manual data” gap some companies cited).
●Considerations: Requires lab digitization (lab-information management systems, standardized formats).
Regulatory compliance, risk modeling & ethics checks
●What: AI helps model ecological and zoonotic risk scenarios of modified animals and aids documentation for regulatory submissions.
●Benefit: Improves risk assessment rigor and shortens regulatory review time if accepted.
●Considerations: Models must be transparent and auditable to be useful for regulators.
R&D & commercial scale
●Explanation: Strong R&D ecosystems, large animal-health firms (e.g., listed top players), and capital markets support both biotech startups and scale-ups.
●Example from data: Elanco invested >USD 130M (Aug 2024) to expand US biologics production — shows manufacturing capacity expansion.
Regulatory & institutional support
●Explanation: Active regulatory agencies and government programs drive adoption of diagnostics and biologics, enabling commercialization.
Market dynamics
●High veterinary clinical penetration → strong recurring demand for vaccines/diagnostics and premium therapeutics.
Demand drivers
●Rapid growth in middle-class incomes, increasing pet ownership, and rising animal-protein consumption.
Aquaculture prominence
●China stats cited: per-capita aquatic product consumption reached 50.48 kg (2023); China produced 23.95 million tons of marine aquaculture (2023) — heavy demand for aquaculture biotech.
Local innovation
●Local companies (e.g., Ringbio ELISA kit July 2024) and national programs accelerate deployment.
Regulatory & infrastructure variability
●Opportunity & challenge: markets differ widely by country (China, India, Japan, South Korea, Thailand), so commercialization strategies must be localized.
Regulation & welfare focus
●Explanation: Strong emphasis on animal welfare, sustainability and rigorous regulation – favorable to high-quality vaccines, diagnostics and welfare-oriented biotech.
Government funding & surveillance
●Example: UK £10M (May 2025) Gap-DC genomics funding for pathogen surveillance — demonstrates public investment in genomics.
Large cattle population & dependency
●Explanation: India has the world’s largest cattle population and animal husbandry supports two-thirds of rural population — strong domestic demand for vaccines, reproduction technologies and diagnostics.
Government R&D funding areas
●Focus areas: transgenic animal development, reproduction, genome characterization of native breeds, vaccines, diagnostics and transgenesis-based biopharma.
Aquaculture & food security
●Huge aquaculture scale (see China stats above) → major market for vaccines, diagnostics and feed-efficiency biotech.
Domestic R&D
●Local product launches (e.g., ELISA test kits) indicate growing domestic capabilities.
Veterinary services & market structure
●Data: >28 million pets may demand care; ~6,080 veterinary-industry companies — large service base that sustains demand for diagnostics and clinic-level biotech.
Opportunity areas
●Large livestock sectors, expanding demand for productivity tools and vaccines.
Infrastructure & regulatory variability require tailored entry strategies.
Rising demand for animal products
●Global population growth and higher incomes increase demand for meat, dairy and aquaculture, which drives adoption of biotech to raise productivity and food safety.
Technological advances
●CRISPR, recombinant DNA, NGS/PCR diagnostics and improved vaccine platforms increase product efficacy and lower time-to-market.
Investment and capacity expansion
●Significant corporate investments (e.g., Elanco’s US expansion) and private funding (Animab, Colossal) accelerate commercialization.
Public health & food-safety concerns
●Need to control zoonoses, antibiotic residues and ensure safe protein supply increases demand for diagnostics and biologics.
Ethical concerns & public acceptance
●Genetic modification and de-extinction work triggers ethical debates; consumer resistance and regulatory hurdles can slow adoption.
Regulatory complexity
●Multiple, sometimes inconsistent regulations across regions increase time and cost to commercialize genetically engineered animals and some biopharmaceuticals.
Data & infrastructure gaps
●Adoption of AI and advanced diagnostics requires digitized farm data and lab capacity, which is uneven globally.
Precision breeding & gene editing
●CRISPR and precision breeding offer clear productivity and environmental footprint reductions — major commercial upside.
Vaccines & recombinant biologics
●Continued demand for safe, scalable vaccines and recombinant therapeutics (monoclonals, proteins) for livestock and companion animals.
Aquaculture biotechnology
●Rapidly growing aquaculture market open to vaccines, diagnostics, and nutrition biotech.
AI-enabled diagnostics & farm analytics
●AI allows scaling diagnostics and early disease detection—reduces loss and improves welfare.
Consolidation & spinouts
●Large pharma divestitures (Bayer → Elanco note) and spin-outs (Zoetis split from Pfizer historically noted in your content) concentrate expertise and capital in specialist animal health players.
Partnerships & cross sector collaboration
●Collaborations between biotech, pharma, agtech and data firms accelerate product development (examples in funding and expansion).
●Products: Veterinary vaccines, pharmaceuticals, diagnostics, biologics.
●Overview: Global leader focused exclusively on animal health (named in your list).
●Strengths: Broad product portfolio across companion and production animals; deep distribution channels and R&D pipeline.
●Products: Vaccines, parasiticides, therapeutics and diagnostics.
●Overview: Big-pharma animal health division with global reach.
●Strengths: Large R&D base, regulatory experience and global commercialization capability.
●Products: Veterinary biologics, pharmaceuticals, vaccines and production-animal solutions.
●Overview: Major animal health player that has expanded manufacturing (noted USD 130M+ investment Aug 2024).
●Strengths: Manufacturing capacity, large commercial footprint, acquisitions/consolidation history (includes Bayer Animal Health assets).
●Products: Vaccines, parasiticides, animal therapeutics.
●Overview: Large, research-intensive firm in veterinary biologics.
●Strengths: Strong vaccine R&D and broad international presence.
●Products: Vaccines, parasiticides, biologics and diagnostics for livestock and companion animals.
●Overview: Focused animal health company with global commercialization.
●Strengths: Strong in production-animal vaccines and field services.
●Products: Pharmaceuticals, vaccines and nutritional products for companion and production animals.
●Overview: Specialist animal health company.
●Strengths: Niche product strengths and longstanding vet relationships.
●Products: Veterinary diagnostics (ELISA, immunodiagnostics), lab services and analytics.
●Overview: Diagnostics leader in clinic/lab testing (appears in your list).
●Strengths: Wide diagnostics footprint in veterinary clinics and strong test portfolio.
●Products: Lab equipment, molecular diagnostics platforms, reagents and analytical instruments used across animal biotech R&D and diagnostics.
●Overview: Major supplier of laboratory infrastructure to the sector.
●Strengths: Global supply chain and instrument/service ecosystem enabling diagnostics and R&D workflows.
●Products: Genetics and breed improvement services (e.g., bovine/pork genetics).
●Overview: Specialist in animal genetics and selective breeding.
●Strengths: Proprietary genetic lines, breeding programs and commercial scale for livestock genetics.
●Products: Food and animal safety diagnostics, ELISA kits, molecular tests and feed safety products.
●Overview: Focus on food-safety and animal diagnostics with commercial test kits (listed in your list).
●Strengths: Diagnostics + food-safety product portfolio that serves processors and farms.
Animab EUR 10M Series B (July 2025)
●Announcement: Animab closed EUR 10 million Series B to advance oral antibody therapeutics for production animals.
●Implication: Investor appetite for non-antibiotic biologics for production animals — signals commercialization potential for oral immunotherapies and alternatives to antibiotics.
Colossal Biosciences $200M Series C (Jan 2025)
●Announcement: TWG Global and others provided $200M Series C; Colossal positions itself as a de-extinction/genetic engineering firm.
●Implication: High-risk, high-profile capital flows into advanced genetic engineering; raises technical, ethical and regulatory debates but also accelerates platform development.
Elanco USD 130M+ production expansion (Aug 2024)
●Announcement: Investment to expand Kansas biologics manufacturing by 25,000 sq ft.
●Implication: Increased biologics capacity (vaccines/biologics) — better supply resilience, scale for domestic demand.
UK £10M genomics funding (May 2025)
●Announcement: Funding for the Genomics for Animal and Plant Disease Consortium (GAP-DC) to boost pathogen surveillance.
●Implication: Stronger pathogen genomics surveillance capabilities will help early detection and containment — benefits both animal health and food security.
Biovet (Bharat Biotech group) LSD vaccine launch (May 2025)
●Announcement: Novel lumpy skin disease vaccine introduced in Andhra Pradesh.
●Implication: Regionally relevant vaccines addressing livestock disease; shows rapid translation of biotech to local needs.
NIAB diagnostics achievement (Sept 2024)
●Announcement: New diagnostic methods to detect antibiotics in animal food samples.
●Implication: Stronger food safety control and compliance tools; helps manage antibiotic residue concerns.
Ringbio ELISA test kit (July 2024)
●Announcement: ELISA kit for Brucella strain detection across multiple species.
●Implication: Local diagnostic innovation improving zoonosis detection systems.
Olden Labs commentary (May 2024)
●Observation: Animal research R&D is still manually recorded in many labs; need for digitization and modern workflows.
●Implication: A clear market opportunity for lab digitization, data platforms, and AI-enabled R&D tools.
Vaccine & biologics commercialization (Biovet / Elanco expansion)
●Implication: Faster deployment of animal vaccines and increased production capacity.
Diagnostics & food-safety tools (NIAB, Ringbio, Neogen presence)
●Implication: Stronger detection tools across food and animal supply chains; improves compliance and export readiness.
Funding into next-generation therapeutics (Animab, Colossal)
●Implication: Capital is available for novel biologics and high-tech genetic ventures; expect more clinical/field trials and partnerships with incumbents.
Public genomics surveillance programs (UK GAP-DC)
●Implication: Public investment in pathogen genomics will reduce outbreak risk and support more targeted vaccination strategies.
Calls for digitization (Olden Labs)
●Implication: Upside for companies offering LIMS, image analytics, and ML pipelines for animal R&D.
Vaccines
●Types: Live attenuated, inactivated, DNA vaccines, recombinant vaccines.
●Role: Primary prevention for endemic and epidemic animal diseases; dominant revenue source in 2024.
●Key issues: Safety, cold-chain, strain coverage, and cost per dose.
Diagnostics
●Subtypes: Immunodiagnostics (ELISA, lateral flow), molecular diagnostics (PCR, qPCR), biosensors.
●Role: Disease surveillance, antibiotic-residue testing, and food-safety screening.
Therapeutics
●Subtypes: Monoclonal antibodies, recombinant proteins, novel small molecules.
●Role: Treatment of infectious and chronic conditions; biopharmaceuticals for companion animals and high-value production animals.
Genetic Engineering
●Subtypes: Transgenic animals, gene-editing tools (CRISPR, TALEN).
●Role: Create traits (disease resistance, productivity) and biopharming (therapeutic protein production).
Reproductive Technologies
●Subtypes: Artificial insemination (AI), embryo transfer (ET), in-vitro fertilization (IVF), somatic cell nuclear transfer.
●Role: Accelerate genetic improvement and breed propagation.
Nutrition-based Biotechnology
●Subtypes: Probiotics, enzymes, nutritional genomics.
●Role: Improve feed conversion, gut health and reduce antibiotic use.
●Livestock (cattle, sheep, pigs) — largest market share in 2024; drivers include meat/dairy demand.
●Poultry (chickens, turkeys) — high throughput sector with vaccine/diagnostic needs.
●Companion animals (dogs, cats) — rising pet adoption increases premium therapeutics and diagnostics demand.
●Aquaculture (fish, shrimp) — fastest-growing animal type; key for feed efficiency, vaccines and diagnostics.
●Other (horses, rabbits) — niche but high-value segments.
●Veterinary clinics — frequent point-of-care diagnostic and vaccine administration; dominated 2024 usage.
●Animal research institutes — drive transgenic and basic R&D.
●Biopharmaceutical companies — large purchasers of genetically engineered animals, contract manufacturing and biopharming.
●Livestock farms — mass adoption targets for vaccines, feed-biotech and reproduction tech.
●Academic & government institutions — lead surveillance, policy and early-stage R&D.
●Genetic engineering — primary R&D driver and market leader in 2024.
●Cloning and cell culture — enable transgenics and therapeutic production.
●Recombinant DNA technology — expected fastest CAGR during forecast period.
●PCR/NGS-based diagnostics — backbone of modern molecular disease surveillance.
Q1: What is the current size and forecast for the global animal biotechnology market?
A: The market was USD 28.17 billion in 2024, grew to USD 30.97 billion in 2025, and is projected to reach USD 72.6 billion by 2034, with a CAGR of 9.93% from 2025–2034.
Q2: Which product segment generated the most revenue in 2024?
A: Vaccines captured the dominant revenue share of the market in 2024.
Q3: Which region led the market in 2024 and which is growing fastest?
A: North America dominated the market in 2024; Asia Pacific is expected to show the fastest CAGR during the forecast period.
Q4: What are the biggest opportunities and restraints in this market?
A: Opportunities: precision breeding/gene editing (CRISPR), aquaculture biotech, recombinant biologics and AI-enabled diagnostics. Restraints: ethical concerns about genetic modification, regulatory complexity, and data/infrastructure gaps.
Q5: Which technologies are expected to grow fastest?
A: Genetic engineering is a leader (2024), while recombinant DNA technology is expected to exhibit the highest CAGR during the forecast period.
Access our exclusive, data-rich dashboard dedicated to the biotechnology sector – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/price/5849
Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Powering Healthcare Leaders with Real-Time Insights: https://www.towardshealthcare.com/healthcare-intelligence-platform
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Web: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest
The global digital health and wellness market is projected to expand from US$ 498.99 billion in 2024 to US$ 3,568.11… Read More
The global radiopharmaceutical market is projected to grow from USD 6.8 billion in 2024 to USD 14.11 billion by 2034,… Read More
The U.S. life science market is on an upward trajectory, poised to generate substantial revenue growth, potentially climbing into the… Read More
The U.S. cell therapy market size is forecast to grow at a CAGR of 21.46%, from USD 8.04 billion in… Read More
The global ophthalmology devices market was US$ 7.51 billion in 2024, rose to US$ 7.89 billion in 2025, and is… Read More
The global digital microfluidics systems on a chip market is on a rapid growth path — poised to generate hundreds… Read More